Search PubMed⌕ Search

Biomedical subjects

Arnon Blum

Publications and source records attributed to Arnon Blum.

29 records · Page 2Linked to original sources
PubMed2003

The role of T-lymphocyte subpopulations in acute myocardial infarction.

T lymphocytes have the potential to affect atherosclerosis at different stages of the process. They play an active role in acute myocardial infarction (AMI) and myocardial damage, and may affect the clinical outcome of patients with coronary artery disease. CD40 ligand expression on T lymphocytes promotes the expression of matrix-degrading enzymes in vascular smooth muscle cells and may thus establish a new pathway of immune-mediated destabilization of the human atheroma. The major class of T lymphocytes present in atherosclerotic lesions is CD4+. CD4+ cells differentiate into Th1 and Th2 lineage in response to the local milieu of cytokines. Much of the emphasis in atherosclerosis research is focused on the role of Th1 type responses.

Journal Article↗
PubMed2003

The prognostic value of high-sensitive C-reactive protein and cardiac troponin T in young and middle-aged patients with chest pain without ECG changes.

BACKGROUND: There is growing evidence of the prognostic importance of inflammatory markers in angina pectoris. However, the independent value of high-sensitive C-reactive protein (hsCRP), cardiac troponin T (cTnT), or their combination has not been established in young patients with angina pectoris without ECG changes. Therefore, we assessed the 6-month prognostic values of serum hsCRP and cTnT in young and middle-aged patients who were admitted to the hospital with chest pain but without ECG changes. METHODS: Forty young or middle-aged patients (45+/-10 years old; two females) were included in the study. All had chest pain for the first time without ST-T changes or any other ECG changes and with normal CPK-MB levels. Blood was drawn on admission, separated, and serum was frozen at -80 degrees C for 1 year until thawed and studied as one batch in order to measure hsCRP and cTnT levels. A clinical follow-up was done for 6 months. RESULTS: Our findings showed that the strongest independent marker of an adverse outcome was the hsCRP level on admission (sensitivity 66.7%; specificity 94.1%); cTnT level added a little to the specificity (97.1%), but did not add to the sensitivity that was found by hsCRP level. CONCLUSIONS: hsCRP level on admission could be an independent prognostic marker in young and middle-aged patients with angina pectoris without ECG changes and without CPK-MB elevation.

Journal Article↗
PubMed2003

Effects of oral soy protein on markers of inflammation in postmenopausal women with mild hypercholesterolemia.

BACKGROUND: Nitric oxide (NO) may protect arteries against atherosclerosis, as suggested by experimental studies. Estrogen therapy enhances the bioactivity of NO in the vasculature of healthy postmenopausal women, but is not acceptable for long-term use by many women. Observational studies have demonstrated beneficial cardiovascular effects of soy protein in premenopausal and postmenopausal women. We examined whether the consumption of isolated soy protein may improve markers of vascular inflammation in postmenopausal women with hypercholesterolemia. METHODS AND RESULTS: In a randomized, double-blind, placebo-controlled, crossover study, 24 postmenopausal women with hypercholesterolemia received 25 g of soy protein or a placebo daily for 6 weeks, with treatment periods separated by 1 month. Markers of vascular inflammation were measured by enzyme-linked immunosorbent assay methods, including: soluble interleukin-2 receptor (sIL-2r), E-selectin, P-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1). There was no effect of soy protein in comparison with placebo on the inflammatory markers: the sIL-2r level was 942.2 +/- 335.3 pg/mL with soy protein and 868.5 +/- 226.9 pg/mL with placebo (P =.311); E-selectin was 39.6 +/- 16.5 ng/mL with soy protein and 42.1 +/- 17.6 ng/mL with placebo (P =.323); P-selectin was 157.9 +/- 67.9 ng/mL with soy protein and 157.5 +/- 47.6 ng/mL with placebo, (P =.977); ICAM-1 was 266.0 +/- 81.3 ng/mL with soy protein and 252.5 +/- 82.7 ng/mL with placebo (P =.435); VCAM-1 was 402.7 +/- 102.1 ng/mL with soy protein and 416.4 +/- 114.8 ng/mL with placebo (P =.53). CONCLUSIONS: Consumption of 25 g of isolated soy protein daily for 6 weeks does not substantially affect markers of vascular inflammation in postmenopausal women with hypercholesterolemia.

Biomarkers↗
PubMed2003

First-degree atrioventricular block and restrictive physiology as cardiac manifestations of Fabry's disease.

Fabry's disease is an X-linked disorder of glycosphingolipid catabolism related to the defective activity of glycosphingolipid, mainly ceramide trihexoside, in the vascular smooth muscle, myocardium, cells of the sympathetic central nervous system, and epithelial cells of renal glomeruli. We describe a young man who had Fabry's disease and unusual electrocardiographic and echocardiographic patterns at admission for treatment of left leg cellulitis. Findings included a prolonged PR interval and a right bundle branch block pattern, no echocardiographic signs of septal or hypertrophic cardiomyopathy, and a restrictive physiologic pattern. This pattern of electrocardiographic and echocardiographic characteristics of Fabry's disease has not been reported previously and should be added to the other cardiac manifestations of Fabry's disease.

Adult↗
PubMed2003

Effects of soy protein on endothelium-dependent vasodilatation and lipid profile in postmenopausal women with mild hypercholesterolemia.

BACKGROUND: Estrogens appear to improve endothelium-dependent systemic and coronary vasodilator function, perhaps by increasing nitric oxide levels and the subsequent effect of nitric oxide on endothelial function and smooth-muscle relaxation. Because soybean foods contain phytoestrogens, we evaluated the effect of orally administered soy proteins on vascular responsiveness. METHODS: This double-blind, placebo-controlled crossover study involved 24 postmenopausal women (mean age 55 yr) who were hypercholesterolemic, who were not taking hormone replacement therapy and had not taken antioxidants or lipid-lowering agents in the preceding 2 months. The patients were randomized to receive a 25-g soy protein supplement or a mild protein placebo for 6 weeks, separated by a washout period of 4 weeks. To evaluate nitric oxide bioactivity we used ultrasonography to measure endothelium-dependent dilator responses in the brachial artery to hyperemia. We induced hyperemia by inflating a blood pressure cuff on the forearm to 250 mm Hg for 5 minutes. We also determined the effect of the supplements on various lipids. RESULTS: The mean (+/- standard deviation) brachial artery diameter was similar in both groups (3.94 [0.79] mm in the placebo group and 4.13 [0.74] mm in the soy protein group). In both placebo and protein groups, the serum triglyceride levels increased, and total cholesterol and low-density lipoprotein cholesterol levels fell significantly (p < 0.05). High-density lipoprotein cholesterol levels were little changed. INTERPRETATION: Consumption of a supplement of 25 g of soy protein daily for 6 weeks had no measurable effect on arterial diameter or vasodilatation in response to hyperemia.

Cholesterol↗
PubMed2000

CME Paper: Hormone Replacement Therapy for Prevention or Treatment of Atherosclerosis in Postmenopausal Women: Promises, Controversies, and Clinical Trials.

Cardiovascular disease is the leading cause of death among men and women in the U.S. and other developed societies. However, myocardial infarction and stroke are uncommon in women until their sixth decade and beyond. Clinicians have long suspected that the delay of a decade or more in cardiovascular disease expression in women relative to men is due to the protective effects of estrogen prior to menopause. Reports from population based observational studies of the favorable effects of hormone replacement therapy on cardiovascular morbidity and mortality have led to enthusiasm for widespread use of estrogen by postmenopausal women for the prevention of cardiovascular disease. In support of the antiatherogenic potential of estrogen are studies in postmenopausal women showing favorable effects on lipoprotein levels, fibrinolysis, and vascular function. However, a secondary prevention trial in postmenopausal women with coronary artery disease showed no cardiovascular benefit of hormone replacement therapy. Ongoing clinical trials and options to conventional hormone replacement therapy for cardiovascular protection will be discussed in this review. (c)2000 by CVRR, Inc.

Journal Article↗
PubMed1999

The effects of L-arginine on atherosclerosis and heart disease.

L-arginine, a semi-essential amino acid, can enhance the synthesis of nitric oxide (NO) via the nitric oxide synthase pathway. Enhanced bioavailability of NO may prevent activation of pro-inflammatory endothelial genes by the inhibition of nuclear transcription factor NF 3B, thus preventing the expression of adhesion molecules on endothelial surfaces. Animal studies have demonstrated that the chronic administration of L-arginine reduces the extent of atherosclerosis and prevents xanthoma development in LDL receptor knockout mice. Human studies have demonstrated improvement in endothelium vasodilator function both in coronary arteries and forearm flow responses. In addition oral L-arginine reverses an increased monocyte-endothelial adhesion in men with coronary artery disease and normalizes platelet aggregation in hypercholesterolemic humans. L-arginine may be a promising drug in the therapy of atherosclerosis. (Int J Cardiovasc Interventions

Journal Article↗